Convenience drives research into transdermal patches, sublingual formulations, and improved oral delivery systems
Shults CW, Flint Beal M, Song D, Fontaine D
The no-DAC blind spot One more point deserves emphasis because it is routinely ignored in marketing copy: every piece of the human evidence above is for CJC-1295 with DAC
in vitro and animal studies have linked thymosin beta-4 overexpression to increased tumor size and metastasis in several cancer types (including colorectal and pancreatic cancer), leading researchers to flag a theoretical cancer-promotion risk, particularly for anyone with an active malignancy or recent cancer history Self-reported effects compiled from user and case reports, not controlled trials, include injection-site redness or itching, transient fatigue, and headache
These established therapies should generally be considered first-line treatments unless contraindicated or ineffective for individual patients